RxDoctor Payments Data

Michelle Lindsey, NP

Family · Kenner, LANPI 1295089217

Payments from drug & device makers

$1,054in general payments, 2019–2025

Across 48 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Novo Nordisk$181
  • Lilly USA, LLC$111
  • Exact Sciences$81
  • AstraZeneca$57
  • Pfizer$55
  • plus $296 from 9 others

What the payments were for

  • Food & beverage$1,054100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,054 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$16,205
Medicare patients
143
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$33,929
LinzessLinaclotide34$24,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,314
JardianceEmpagliflozin12$15,012
FarxigaDapagliflozin Propanediol19$10,811
Albuterol Sulfate HfaAlbuterol Sulfate35$1,021
Pregabalin50$993
Levocetirizine Dihydrochloride82$979
Triamcinolone Acetonide17$780
Fluticasone Propionate28$776
Desloratadine17$699
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort12$661
ValacyclovirValacyclovir Hcl11$633
Diclofenac Sodium18$587
Potassium Chloride18$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$111$33,92929 claims
AbbVieLinzess$273$24,72934 claims
Boehringer IngelheimJardiance$16$15,01212 claims
AstraZenecaFarxiga$57$10,81119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.

Other family in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →